| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sanofi-Aventis SA > News item |
Sanofi meta-analysis shows benefits of Taxotere
By Elaine Rigoli
Tampa, Fla., June 5 - Sanofi-aventis announced that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients receiving Taxotere (docetaxel) injection concentrate had demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid (vinorelbine or vindesine) regimens.
The trials used Taxotere and vinca-alkaloids alone or in combination as first-line therapy for advanced non-small cell lung cancer. Six of the trials compared Taxotere to vinorelbine regimens and one to a vindesine regimen.
The pooled results of the seven trials conducted on a total of 2,867 patients show that Taxotere regimens significantly improved overall survival compared to vinca-alkaloid regimens in this patient population, according to a news release.
The comparison was done on a total of 1,638 patients who received Taxotere regimens and 1,229 who received vinca-alkaloid regimens.
The meta-analysis also demonstrated that the benefit derived from Taxotere therapy persisted after exclusion of the vindesine study and also when monotherapy regimens were excluded from the analysis.
While neutropenia was a common adverse event in the trials, it was significantly less frequent with Taxotere than with vinca-alkoloid regimens, as was febrile neutropenia, a condition marked by fever and decrease in the number of a type of white blood cells that helps fight infection, the release said.
The findings of the meta-analysis are in line with the results of the pivotal TAX 326 study, which provided the basis for the Taxotere approval in the first-line treatment of non-small cell lung cancer.
Sanofi-aventis is a global pharmaceutical company located in Paris.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.